



Business Development & Licensing

- **Products Under Development**

Key Project Pipeline

Licensing In

Licensing Out

Products Under Development

Neridronate is an amino-bisphosphonate used in Metabolic Osteopathy and is the first drug to have obtained the Italian Health Authorities designation for a "rare disease" such as Osteogenesis Imperfecta. Clinical studies are currently being completed to support this drug in new therapeutic indications.

In the Osteoarticular field, studies are also underway for new products with a strong chondro-protective action to be used in Osteoarthritis.

In the Neurological field, new compounds are being developed with interesting anxiolytic and anti-depressant properties that through entirely new mechanisms of action, represent innovative and advantageous approaches in both efficacy and tolerability compared to standard therapies.